1 / 35

Director’s Report to the National Advisory Council on Drug Abuse

Director’s Report to the National Advisory Council on Drug Abuse. May 16, 2007. Director’s Report to the National Advisory Council on Drug Abuse. Budget Update. What’s New @ NIH?. Recent NIDA Activities. NIDA BUDGET. (Thousands). 2007 C.R. 2008 P.B. 2005 Actual. 2006 Actual.

josiah
Download Presentation

Director’s Report to the National Advisory Council on Drug Abuse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Director’s Report to the National Advisory Council on Drug Abuse May 16, 2007

  2. Director’s Report to the National Advisory Council on Drug Abuse Budget Update What’s New @ NIH? Recent NIDA Activities

  3. NIDA BUDGET (Thousands) 2007C.R. 2008P.B. 2005Actual 2006Actual $693,282 $698,976 $699,349 $300,073 $999,422 $699,908 $300,457 $1,000,365 +0.1% NonAIDS $313,137 $299,882 AIDS $1,006,419 $998,858 TOTAL Increase Over Prior Year +1.2% -0.8% +0.1%

  4. RPG* Funding, Unsolicited and Solicited Funding (in billions) * Research Projects are part of research grants, limited to activity codes R01, R03, R15, R21, R22, R23, R29, R33, R34, R35, R36, R37, R55, R56, P01, P42, PN1, UC1, U01, U19 and DP1. No NLM awards are considered to be research projects. Solicited awards are responses to Requests for Applications (RFA’s).

  5. Success Rates of Solicited and Unsolicited Competing RPG* Applications * Research Projects are part of research grants, limited to activity codes R01, R03, R15, R21, R22, R23, R29, R33, R34, R35, R36, R37, R55, R56, P01, P42, PN1, UC1, U01, U19 and DP1. No NLM awards are considered to be research projects. Solicited awards are responses to Requests for Applications (RFA’s).

  6. I/C’s are arrayed by percent of funding for new RPG’s spent for responses to program announcements in FY 2006

  7. NIDA Dashboard New PIs ? ? Collaborations Medicinal Chemists -- Recruitment -- Training ?

  8. FY 2008 Budget Hearings • March 1, 2007 -- House Appropriations Subcommittee on Labor, HHS • and Education Hearing on FY 2008 President’s Budget Request for • SAMHSA, NIDA, NIAAA and NIMH • March 6, 2007 -- House Appropriations Subcommittee on Labor, HHS • and Education Hearing on FY 2008 President’s Budget Request for NIH • March 19, 2007 – Senate Appropriations Subcommittee on Labor, HHS • and Education Hearing on FY 2008 President’s Budget Request for NIH • March 26, 2007 – Senate Appropriations Subcommittee on Labor, HHS, • and Education FY 2008 Budget for Mind, Brain and Behavioral Research

  9. IC Directors’ Retreat – May 17-18, 2007 Roadmap II Strategic Planning Groups Top 5 Topics 1) Microbiome 2) Protein Capture/Proteome Tools 3) Phenotyping Services, Tools 4) Inflammation 5) Epigenetics a) Training/Careers b) Health Disparities c) Science of Science d) Pharmacogenomics

  10. Epigenetic Mechanisms Regulate How Genetic Information Is Expressed Across Development, Tissue, Environment and Disease States Citations for Epigenetics 4500 4000 • DNA Methylation – silences gene • Histone Modification – methylation, acetylation, or phosphorylation • Non coding RNA 3500 3000 2500 2000 1500 1000 500 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 Epigenetics + Disease Epigenetics

  11. Epigenetic Marks Are Altered in Common Brain Disorders Including Addiction

  12. Timeline for Epigenetics Program FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 JUMPSTART • International Consortium • Standardization • Reagents (Abs) • 24 comprehensive reference epigenomes • Cell/tissue variation assessed • New Ab reagents for epigenomics • Public resource (cells/tissue, data, tools) RFA#1 Mapping Centers RFA#2 RFA1 RFA2 RFA3 RFA4 RFA5 RM/IC Projects Co-fund up to 15 IC-based programs RFA#3 • Establish/maintain public data resource (via NCBI) • New tools for data integration, analysis, and viewing TRANSITION to ICs Data Management Center RFA2 RFA#4 RFA1 RFA3 RFA4 Technology Development Develop/adapt new tools, application to RM and IC projects

  13. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Donna M. Jones (Acting) Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  14. Success Rates for AIDS Extramural and Non-AIDS Extramural Percent

  15. Strategies of NIDA’s Investment on AIDS FY06 FY07 FY08 FY09 FY10 $65M ~$60M ~$60M $58M $40M Uncommitted Funds • NIDA Staff Meetings • to identify priority areas • March 12, 2007 • April 9, 2007 • Scientific Meeting of • Experts • May 8-9, 2007 In collaboration with: National Institute on Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute of Child Health and Human Development National Institute of Mental Health Centers for Disease Control and Prevention

  16. Changing Nature of the HIV Epidemic

  17. HIV/AIDS Mechanisms • Infrastructure: • facilitate access to existing cohorts (ALIVE, MLS) • proteomic analysis • animal models • Innovative research: • Avant-Garde Award (equivalent to Pioneer Award) • International: • Create clinical and basic research networks • Training: e.g., Invest Fellows/China/CTN • Integrate research with NIAID international networks

  18. Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting) NIDA National Institute on Drug Abuse Director, AIDS Research Special Populations Office Office of Extramural Affairs Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DESPR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  19. 20 20 15 15 10 10 5 5 0 0 Non-Injectors Current Injectors Non-Injectors Current Injectors Convergence of HIV Seroprevalence Among Injecting and Non-injecting Drug Users Drug Treatment Program Respondent-Driven Sampling (n=448 2004) (n=2121 2001-2004) 17% 15% CI 12-21% 13% CI 11-19% 12% CI 12-15% CI 9-16% HIV Prevalence Source: Des Jarlais et al AIDS, 21: 231-235, 2007.

  20. Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting) NIDA National Institute on Drug Abuse Director, AIDS Research Special Populations Office Office of Extramural Affairs Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DCNBR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  21. Sexual & Drug Behavior Patterns & HIV & STD: Racial Disparities National Longitudinal Longitudinal Study of Adolescent Health. 18 to 26 years old Caucasian (n=6257) AA (n=2449) 35 30 25 20 Prevalence HIV /STD 15 10 5 0 Few partners, low ATOD Binge drinking THC use Multiple partners Sex money IDU MSM Drug use Young caucasians are atelevated HIV risk when they engage in risky behaviors; whereas young AAare at high risk even when theirbehaviors are normative. Source: Hallfors et al Am J Public Health. 2007 97:125-32, 2007.

  22. Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting) NIDA National Institute on Drug Abuse Director, AIDS Research Special Populations Office Office of Extramural Affairs Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DBNBR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  23. Effectsof Statins on the Interactions of HIV-1-Infected T Cells with Neurons With and Without ETOH on the Oxidative Stress Marker,Heat Shock Protein 70 (Hsp70) Ator, atorvastatin; Simva, simvastatin 0.3% EtOH Statins Protect Human Neurons against EtOH- & HIV Type 1-Induced Oxidative Stress In Vitro Source: Acheampong et al. J Virol. 81:1492-1501, 2007.

  24. Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting) NIDA National Institute on Drug Abuse Update from Dr. Betty Tai this morning Director, AIDS Research Special Populations Office Office of Extramural Affairs Office of Science Policy & Communications Center for the Clinical Trials Network CCTN Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  25. 1,000,000 people in USA are infected with HIV 40,000 new cases each year 25 % of persons with HIV are unaware they are infected ¼ of persons who test HIV+ fail to return to receive results CDC now recommends offering routine HIV testing to persons at risk for HIV Integrating HIV Rapid Testing and Counseling into Drug Treatment HIV Rapid Test • FDA approved • blood from a finger stick or oral fluid • 20 minutes • $12-15/kit • can be done by counselors

  26. Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Donna M. Jones Executive Officer (Acting) Office of Planning & Resource Management Donna M. Jones (Acting) NIDA National Institute on Drug Abuse Director, AIDS Research Special Populations Office Office of Extramural Affairs Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DPMCDA David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  27. Injectable Sustained-Release Naltrexone for Opioid Dependence Treatment Sustained release naltrexone produced a robust, dose-relatedincrease in treatment retention and in drug-free urines in heroin dependent subjects (n=60) Source: Comer et al., Arch Gen Psychiatry. 63:210-218, 2006.

  28. Brain Imaging Drug Use Prevention Messages (R21) (RFA-DA-07-007) – 16 Applications DCNBR and DESPR

  29. Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (R01--RFA-DA-07-002) – 14 Applications (R21--RFA-DA-07-003) – 13 Applications Extinction and Pharmacotherapies for Drug Addiction (R01--RFA-DA-07-010) -- 15 Applications (R03--RFA-DA-07-011) -- 12 Applications

  30. Design, Synthesis, and Preclinical Testing of Potential Treatment Agents for Drug Addiction (R01) (RFA-DA-07-006) – 30 Applications Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction (U01) (RFA-DA-07-004) – 5 Applications

  31. Recent and Upcoming Meetings, Conferences and Events

  32. The Addiction Project’s Audience is estimated to be over 50 million impressions…and counting • Including… • HBO Channels – over 13 million viewers • HBO on Demand – nearly 1 million orders • DVD – more than 30,000 sold • Companion Book – over 7,000 sold • Podcasts – over 380,000 downloads • Online – hbo.com/addiction, AOL & cable affiliate websites – over 600,000 • video streams & 2.9 million page views • Local & National Outreach Parties & Screenings – over 32,000 people attended • TV Media Coverage: 35 million viewers (including The Oprah Winfrey Show, • Good Morning America, The View, Lou Dobbs, Larry King Live…)

  33. Timothy P. Condon, Ph.D. Deputy Director, NIDA Gregory Brigham, Ph.D. CRO, Maryhaven Dennis McCarty, Ph.D. Oregon Health Sciences University

  34. ACNP American College of Neuropsychopharmacology Liaison Committee Opportunities and Impediments to Drug Development for Alcoholism and Other Substance Abuse The National Press Club Washington, D.C. May 20, 2007

More Related